Результаты поиска

Показания пациентов с множественными миеломными пациентами, прошедшими курс лечения в соответствии со стандартом ухода Idecabtagen Vicleucel.

Idecabtagen vicleucel (ide-cel) был первым утвержденным УЛХ химериком антиген-рецептором Т-клектором для пациентов с множественным миэломой (RRMM). Это было первое исследование для оценки результатов, сообщаемых пациентами (ПИО) среди пациентов, получающих идицель в стандарте медицинского обслуживания (ЗСО). Перспективно оцениваемое качество жизни, связанное со здоровьем (HRQOL), и симптомы, связанные с предвыпуском (исходным уровнем) и днем (D)90 После вливания. Базовые ассоциации ПРО, имеющие характеристики пациентов, средние изменения ПРО и время для стабильных изменений оценивались с помощ

Совпадение в полном тексте источника
… Institutional), Bristol-Myers Squibb (Institutional), National Cancer Institute, and the Leukemia and Lymphoma Society; patents, royalties, other intellectual property: several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy; education or editorial activity: Aptitude …

Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.

Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) expressed in various immune cell types and perform multiple purposes and duties involved in the induction of innate and adaptive immunity. Their capability to propagate immunity makes them attractive targets for the expansion of numerous immunotherapeutic approaches targeting cancer. These immunotherapeutic strategies include using TLR ligands/agonists as monotherapy or combined therapeutic strategies. Several TLR agonists have demonstrated significant efficacy in advanced clinical trials. In recent years, multiple reports est

Совпадение в полном тексте источника
… Also, a slight ligand-mediated activation of TLR5 increased the Treg marker FOXP3 on CD4 + CD25 + Treg cells and increases their immunosuppressive aptitude slightly ( 112 ). … One of the reasons for the growing popularity of TLR agonists for treating tumors is their aptitude to reinstate the activity of immunosuppressed DCs, which can be extremely useful for reversing the immunosuppressive atmosphere inside the TME ( 64 , 65 ). …

Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease.

IntroductionBCMA-directed CAR T-cell therapies have improved outcomes in relapsed and refractory multiple myeloma (MM); however, the majority of patients relapse within 1 to 3 years following treatment. Managing disease progression after CAR T-cell therapy remains a major challenge, particularly in aggressive subtypes including extramedullary disease (EMD) and paramedullary disease (PMD). Real-world data on progression patterns post-CAR T cell therapy and the impact of EMD or PMD on outcomes of patients who relapsed post-CAR T-cell therapy remain scarce.MethodsIn this single-center, retrospect

Совпадение в полном тексте источника
… Education or Editorial Activity: Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, Society for Immunotherapy of Cancer. …

Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention.

AbstractRecent studies demonstrating the feasibility of outpatient chimeric antigen receptor (CAR)-modified T-cell therapy administration are either restricted to CARs with 41BB costimulatory domains or use intensive at-home monitoring. We report outcomes of outpatient administration of all commercially available CD19- and B-cell maturation antigen (BCMA)-directed CAR T-cell therapy using a strategy of no remote at-home monitoring and an early cytokine release syndrome (CRS) intervention strategy. Patients with hematologic malignancies who received CAR T-cell therapy in the outpatient setting

Совпадение в полном тексте источника
… G.S.G.M. reports advisory board/consultancy fees from BMS, BeiGene, Pfizer, Gilead/Kite, Cancer Expert Now, Qessential, and Techspert; honoria from Cardinal Health, DAVA Oncology, Aptitude Health, and Curio Science; and speaking bureau fees from Amgen and Rigel. …

Интеграция арт-терапии и технологии в нейрореабилитацию: обзор аналитического исследования.

Лечение фона Арта становится многообещающим дополнением к нейрореабилитации, обеспечивая творческое участие в улучшении моторных, когнитивных и эмоциональных результатов. Цифровые технологии, такие, как виртуальная реальность (ВПР), усиленная реальность (АР), экзогамы и сенсорные системы, позволяют получить погруженный и интерактивный терапевтический опыт, потенциально повышающий эффективность реабилитации. В рамках этого аналитического обзора проводится систематическая оценка воздействия арт-терапии с использованием технических средств на неврологическую реабилитацию и выявляются эффективные

Совпадение в полном тексте источника
… Creativity represents a core construct underlying art therapy interventions and is defined as “the interaction among aptitude, process, and environment by which an individual or group produces a perceptible product that is both novel and useful within a social context” ( 6 ). …

How I treat cytopenias after CAR T-cell therapy.

Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse toxicities warranting specific recognition and management. Cytopenias occurring after CAR-T infusion invariably manifest early (90 days). Variable etiologies of these cytopenias, some of which remain incompletely understood, create clinical conundrums and uncertainties about optimal management strategies. These cytopenias may cause additional sequelae, decreased quality of life, and increased resource use. Early cytopenias are typically attributed to lymphodepletion chemotherapy, however, infections and hyp

Совпадение в полном тексте источника
… Therapeutics (institutional), Novartis (institutional), bluebird bio (institutional), BMS (institutional), National Cancer Institute, Leukemia and Lymphoma Society; several patents held by the institution in their name (unlicensed) in the field of cellular immunotherapy; education or editorial activity in Aptitude …

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.

Amyloid light-chain (AL) amyloidosis is a rare, typically fatal disease characterized by the accumulation of misfolded immunoglobulin light chains (LCs). Birtamimab is an investigational humanized monoclonal antibody designed to neutralize toxic LC aggregates and deplete insoluble organ-deposited amyloid via macrophage-induced phagocytosis. VITAL was a phase 3 randomized, double-blind, placebo-controlled clinical trial assessing the efficacy and safety of birtamimab + standard of care (SOC) in 260 newly diagnosed, treatment-naive patients with AL amyloidosis. Patients received 24 mg/kg IV birt

Совпадение в полном тексте источника
… Conflict-of-interest disclosure: M.A.G. reports personal fees from Alnylam, Aptitude Health, Ashfield, Celgene, Ionis/Akcea, Janssen, Johnson & Johnson, Juno, Physicians Education Resource, Prothena, Research to Practice, Sanofi, and Sorrento; reports personal fees for data safety monitoring board from …

Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial.

BACKGROUND: Obesity is an established, modifiable risk factor of multiple myeloma (MM); yet, no lifestyle interventions are routinely recommended for patients with overweight or obesity with MM precursor conditions. Prolonged nightly fasting is a simple, practical dietary regimen supported by research, suggesting that the synchronization of feeding-fasting timing with sleep-wake cycles favorably affects metabolic pathways implicated in MM. We describe the design and rationale of a randomized controlled pilot trial evaluating the efficacy of a regular, prolonged nighttime fasting schedule among

Совпадение в полном тексте источника
… Footnotes Conflicts of Interest: IMG has served as a consultant for AbbVie, Adaptive, Amgen, Aptitude Health, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Menarini Silicon Biosystems, Novartis, Pfizer, Regeneron, Sanofi, Standard Biotools, Takeda, The Binding Site, and Window Therapeutics; received …

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.

Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of relapsed/refractory multiple myeloma after 4 lines of therapy. On the KarMMa trial, grade ≥ 3 cytopenias and infections were common. We sought to characterize cytopenias and infections within 100 days after ide-cel in the standard-of-care (SOC) setting. This multi-center retrospective study included 52 patients who received SOC ide-cel; 47 reached day-90 follow-up. Data were censored at day 100. Grade ≥ 3 cytopenia was present among 65% of patients at day 30 and 40% of patients at day 90. Granulocyte colony st

Совпадение в полном тексте источника
… Institutional); patents, royalties, and other intellectual property including several patents held by the institution in his name (unlicensed) in the field of cellular immunotherapy; consulting roles for Cowen, EcoR1, Emerging Therapy Solutions, and Gerson Lehrman Group; and education or editorial activity for Aptitude …

Experiences and Perspectives of Patients with Non-HIV-Associated Lipodystrophies and Their Caregivers: A Qualitative Study.

BackgroundLipodystrophy comprises a group of conditions characterized by loss of functional adipose tissue, resulting in severe metabolic complications and a complex range of symptoms.ObjectiveThis study sought to gain a holistic understanding of the impact of congenital or non-human immunodeficiency virus acquired lipodystrophies on the quality of life of patients and their caregivers and to capture the impact of lipodystrophy on quality of life using a standard instrument.MethodsTen patients with lipodystrophies and five caregivers from the USA and UK were recruited through convenience sampl

Совпадение в полном тексте источника
… Ethics approval The New England Independent Review Board reviewed the study protocol and discussion guide prior to granting an exemption from formal institutional review board review and approval as this study only involves the use of educational tests (cognitive, diagnostic, aptitude, achievement), …

От диагностики к лечению: изучение механизмов, лежащих в основе оптического неврата в множестве склерозов.

Множественный склероз (MS) — хроническое аутоиммунное заболевание, воздействующее на центральную нервную систему, которое, как правило, вызывает сенсорные расстройства, моторную слабость, слабую походку, несогласованность и оптический неуриит (ON). Согласно статистическим данным, до 50% пациентов, страдающих синдромом MS, испытывают проблемы со зрением в период болезни, страдающие от нечеткого зрения, боли, недостатка зрения и даже слепоты. Лечение перешло от кортикостероидов к лечению, ориентированному на клетки В/Т. В рамках этого обзора проводится всеобъемлющая и систематическая оценка диаг

Совпадение в полном тексте источника
… neuronal integrity in in vitro models RMS relapse MS, DHODH dihydroorotate dehydrogenase, RRMS relapsing–remitting MS In brief, a review of current literature indicates that although several DMT medicines may arrest or decelerate additional visual impairment of MS, robust data substantiating their aptitude …

Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions.

Purpose of reviewMultiple myeloma (MM) is a biologically heterogeneous malignancy with relatively uniform treatment paradigms. This review aims to assess the growing role of Minimal Residual Disease (MRD) assessment in facilitating response-adapted therapeutic decision making to individualize therapy in MM.Recent findingsMRD has been repeatedly demonstrated to provide strong prognostic information, superseding traditional IMWG response criteria. The use of MRD to modulate therapy remains controversial. Here, we review the existing landscape of MRD-adapted trial designs in both induction/consol

Совпадение в полном тексте источника
… Declarations Conflict of Interest Benjamin Diamond Honoraria: Sanofi, Janssen Research & Development Consulting or Advisory Role: Sanofi, Janssen Oncology Dickran Kazandjian Employment: University of Miami Hospitals and Clinics Honoraria: Arcellx, BMS, Sanofi, MJH Life Sciences, Curio Science, Aptitude …

Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy.

CAR T-cell therapy is a promising immunotherapy, providing successful results for cancer patients who are unresponsive to standard and traditional therapeutic approaches. However, there are limiting factors which create a hurdle in the therapy performing its role optimally. CAR T cells get exhausted, produce active antitumor responses, and might even produce toxic reactions. Specifically, in the case of solid tumors, chimeric antigen receptor T (CAR-T) cells fail to produce the desired outcomes. Then, the need to use supplementary agents such as immune system modifying immunomodulatory agents

Совпадение в полном тексте источника
… CARs are living drugs that have a great aptitude for cancer immunotherapy [ 1 ]. Chimeric antigen receptor T cells (CAR-T cells) are T cells that are expanded after stimulation and have genetic modifications. …

Physical activity-related health competence and symptom burden for exercise prescription in patients with multiple myeloma: a latent profile analysis.

The purpose of this study is to ensure best possible supply of exercise therapy to patients with multiple myeloma (MM); it is helpful to identify patient groups with similar symptom burden and physical activity-related health competences (PAHCO). Latent profile analyses (LPA) of MM patients were used to identify profiles of patients with similar PAHCO and symptom burden. Analysis of variance was applied to investigate group differences in important covariates. N = 98 MM patients (57% male, age 64 ± 9 years) could be assigned to three distinct PAHCO profiles: 46% were patients with high PAHCO,

Совпадение в полном тексте источника
… Physical activity–related health competence (PAHCO) The questionnaire is based on the PAHCO model outlined above and assesses specific facets of the PAHCO, specifically addressing an individual’s aptitude to effectively utilize PA in order to optimize their overall health. …

Advances in Drug Delivery and Biomaterials: Facts and Vision.

Drug delivery and biomaterials are different fields of science but, at the same time, are tightly related and intertwined. The 2018 CRS Italy Chapter Annual Workshop aims to explore recent advances in design and development in these areas. Many colleagues from Europe participated to the Workshop, stimulating the discussion. To foster the discussion on recent research and networking opportunities, especially among younger attendees, all poster-presenting authors were asked to provide a short talk. The very friendly and stimulating atmosphere allowed the attendees to explore new frontiers and ta

Совпадение в полном тексте источника
… Previous studies reported the aptitude of NP based on chitosan derivatives for internalization by cells and improving the antioxidant activity of the entrapped polyphenols. The total phenolic content (TPC) and the antioxidant ability of CE were measured. … The ability of sponge to release CUR and MTR when applied on L-PRF clot, obtained according to the FDA and CE approved protocol (Intra-spin ® , Intra-lock, Salerno, Italy), and the aptitude of actives to penetrate and/or permeate the membrane were evaluated. …

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.

Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) and 153 patients with no prior BCMA-TT were infused with ide-cel, with a median follow

Совпадение в полном тексте источника
… Institute, CERo Therapeutics, Bristol Myers Squibb, Novartis, Kite/Gilead, Bluebird Bio, and Allogene, patents and royalties from several patents held by the institution in his name (unlicensed) in the field of cellular immunotherapy, and education or editorial activity from BioPharm Communications, ASH, Aptitude …

Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study.

Two-thirds of patients with mucopolysaccharidosis II (MPS II; Hunter syndrome) have cognitive impairment. This phase 2/3, randomized, controlled, open-label, multicenter study (NCT02055118) investigated the effects of intrathecally administered idursulfase-IT on cognitive function in patients with MPS II. Children older than 3 years with MPS II and mild-to-moderate cognitive impairment (assessed by Differential Ability Scales-II [DAS-II], General Conceptual Ability [GCA] score) who had tolerated intravenous idursulfase for at least 4 months were randomly assigned (2:1) to monthly idursulfase-I

Совпадение в полном тексте источника
… Neuropsychol 16 ( 2001 ) 183 – 191 . 14590186 [33] Reynolds C , Conceptual and technical probelms in learning disability diagnosis , in: Reynolds C , Kamphaus W (Eds.), Handbook of Psychological and Educational Assessments in Children: Intelligence, Aptitude and Achievement , Guilford, New York , 2003 …

[XVIII Митинг после ECTRIMS: Обзор новых разработок, представленных на Конгресс ECTRIMS 2025 (Часть I)]

18-е издание совещания Европейского комитета по лечению и исследованию множественной скlerоза (ECTRIMS) прошло 17-18 октября 2025 года в Мадриде, объединив испанских нейрологов, специализирующихся на множественной склерозе (МС), которые представили наиболее значимые достижения, обсуждённые на конгрессе ECTRIMS несколько дней ранее в Барселоне. Целью собрания было обобщить последние достижения в патогенезе, новые критерии диагностики и биомаркеры МС. Эта статья является первой частью двухчастной серии (I и II), которая обзором последних данных о транспортировке клеток в центральную нервную сист

New directions for emerging therapies in acute myeloid leukemia: the next chapter.

Conventional therapy for acute myeloid leukemia is composed of remission induction with cytarabine- and anthracycline-containing regimens, followed by consolidation therapy, including allogeneic stem cell transplantation, to prolong remission. In recent years, there has been a significant shift toward the use of novel and effective, target-directed therapies, including inhibitors of mutant FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase (IDH), the B-cell lymphoma 2 inhibitor venetoclax, and the hedgehog pathway inhibitor glasdegib. In older patients the combination of a hypometh

Совпадение в полном тексте источника
… Smith, PhD, CMPP, Aptitude Health, Atlanta, GA, funded by AbbVie. …

Результаты, сообщенные пациентом после idecabtagen vicleucel vs. ciltacabtajen autoleucel CAR-T для нескольких миелом.

Это было первое исследование, проведенное для оценки сообщаемых пациентами траекторий (PRO) у пациентов с рецидивной/редактированной множественной миеломой (RRMM), получающих стандарт лечения химерика антигенного рецептора T-клектора (CAR-T), и для сопоставления траекторий ПРО в разбивке по лечебным группам, idecabtagene vicleucel (ide-cel) против ciltacabtagene autoleucel (cilta-cel). Участники закончили обследования качества жизни, связанные со здоровьем, и симптомов на уровне охвата/базового уровня (до лимфододостаточности), дня (D) инъекции.0, D7, D14, D21, D30, D60 и D90. Модели кривых ро

Совпадение в полном тексте источника
… Institutional), Bristol-Myers Squibb (Institutional), National Cancer Institute, and the Leukemia and Lymphoma Society; Patents, royalties, other intellectual property: several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy; Education or editorial activity: Aptitude …